CD38 and Miyoshi myopathy: Overall, the 68Ga-anti-CD38 nanobody-based probe was able to recognize all subcutaneous and orthotopic MM lesions to a better extent than the control probes, demonstrating high radiochemical yield (>50%), purity (>99%), and immunoreactivity (>95%) [60].